Table 7.
Treatment management for suspected antiviral resistance (N = 566)
| Mainland China (n = 295) | South Korea (n = 100) | Taiwan (n = 96) | Thailand (n = 75) | |
|---|---|---|---|---|
| On LVD | ||||
| Switch to ADV | 17 | 38 | 22 | 4 |
| Switch to ETV | 2 | 7 | 7 | 7 |
| Add on ADV | 73 | 51 | 65 | 77 |
| Add on ETV | 2 | – | 1 | 5 |
| On ADV | ||||
| Switch to ETV | 27 | 24 | 40 | 18 |
| Switch to interferon | 10 | 2 | 13 | 8 |
| Switch to LVD | 8 | 5 | 8 | 2 |
| Add on LVD | 33 | 19 | 20 | 20 |
| Add on ETV | 15 | – | 15 | 21 |
| Not sure what to do | – | 44 | – | 15 |
| On ETV | ||||
| Switch to ADV | 17 | 8 | 31 | 14 |
| Switch to LVD | 7 | 3 | 6 | 8 |
| Switch to interferon | 18 | – | 28 | 9 |
| Add on ADV | 45 | – | 18 | 31 |
| Add on LVD | 4 | 1 | 4 | 5 |
| Not sure what to do | 2 | 87 | – | 22 |
Values given are in percentages
LVD lamivudine, ADV adefovir, ETV entecavir